Gugulothu Yakaiah (10 results)

Condition: New.

Taschenbuch. Condition: Neu. INTANGIBLE ASSETS IN INDIAN PHARMACEUTICALS | DISCLOSURE PRACTICES AND IMPACT ON VALUE CREATION | Gugulothu Yakaiah | Taschenbuch | Englisch | 2025 | LAP LAMBERT Academic Publishing | EAN 9786208447885 | Verantwortliche Person für die EU: SIA OmniScriptum Publishing, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu. …

PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 256 pp. Englisch.

Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This study analyzed intangible asset (IA) disclosure, trends, and value creation impact in ten Nifty Pharma companies (2015-21). Piramal Enterprises Ltd. led in both mandatory and voluntary disclosures. While most companies showed increasing IA values, their impact on value creation varied. Aurobindo Pharma and Glenmark showed significant IA impact on ROE, ROIC, Tobin's Q, and PB ratio, while Cadila, Divi's, and Dr. Reddy's saw impact on EVA. However, IA had no significant impact on firm value for Biocon, Cipla, Lupin, Piramal, and Sun Pharma in these specific metrics. Overall, IA significantly impacted profitability (ROA, ROE, ROIC, PAT) and firm value (Tobin's Q). Suggestions include improving disclosure for Cadila and Sun Pharma, boosting IA values for Divi's and Lupin, and continuing IA prioritization for Aurobindo and Glenmark to maximize stakeholder value. …

Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This study analyzed intangible asset (IA) disclosure, trends, and value creation impact in ten Nifty Pharma companies (2015-21). Piramal Enterprises Ltd. led in both mandatory and voluntary disclosures. While most companies showed increasing IA values, their impact on value creation varied. Aurobindo Pharma and Glenmark showed significant IA impact on ROE, ROIC, Tobin's Q, and PB ratio, while Cadila, Divi's, and Dr. Reddy's saw impact on EVA. However, IA had no significant impact on firm value for Biocon, Cipla, Lupin, Piramal, and Sun Pharma in these specific metrics. Overall, IA significantly impacted profitability (ROA, ROE, ROIC, PAT) and firm value (Tobin's Q). Suggestions include improving disclosure for Cadila and Sun Pharma, boosting IA values for Divi's and Lupin, and continuing IA prioritization for Aurobindo and Glenmark to maximize stakeholder value.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 256 pp. Englisch. …

Condition: New. Print on Demand.

Condition: New. Print on Demand.

Condition: New. PRINT ON DEMAND.